Elsevier

Digestive and Liver Disease

Volume 49, Issue 10, October 2017, Pages 1133-1138
Digestive and Liver Disease

Liver, Pancreas and Biliary Tract
AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease

https://doi.org/10.1016/j.dld.2017.05.002Get rights and content

Abstract

Background & aims

Liver fibrosis is the single most important prognostic factor in patients with non-alcoholic fatty liver disease (NAFLD). The predictive value of the AST to Platelet Ratio Index (APRI) score, originally developed for fibrosis assessment in hepatitis C virus (HCV) patients, is much less known in the context of NAFLD patients.

Methods

We retrospectively compared the performance of APRI and fibrosis 4 calculator (FIB-4) scores in NAFLD patients with documented liver biopsies, to their performance in chronic HCV patients.

Results

153 patients with biopsy-proven NAFLD and 297 patients with biopsy-proven chronic HCV infection were included. The APRI score was a good predictor for advanced fibrosis in NAFLD patients (area under the ROC curve 0.8307) although it was modestly inferior as compared to the well-validated FIB-4 score (area under the ROC curve 0.8959). The predictive value of APRI score in NALFD patients was inferior as compared to its predictive value in HCV patients (area under the ROC curve of 0.8307 versus 0.9965). In contrast to FIB-4, APRI score was not a good discriminator between intermediate stages of fibrosis in NAFLD patients.

Conclusions

APRI and Fib-4 scores are reasonable tools to allocate NAFLD patients with advanced fibrosis. FIB-4 may better discriminate between intermediate fibrosis stages.

Introduction

Nonalcoholic fatty liver disease (NAFLD) is emerging in recent years as the most prevalent cause for chronic liver disease [1]. NAFLD is also the most common etiology for cryptogenic cirrhosis [2], which may progress to liver failure and hepatocellular carcinoma in a substantial number of patients [3]. While patients with NAFLD who already have advanced fibrosis or cirrhosis are prone to develop severe complications, patients with simple steatosis usually run a benign course and do not appear to have increased mortality as compared to the general population [4]. Therefore, it is important to assess the degree of liver fibrosis in NAFLD patients for surveillance as well as for prognostic purposes [5].

Percutaneous liver biopsy is the gold standard for assessment of the degree of liver inflammation and fibrosis. However, limitations of this procedure include cost, risk of serious complications, a substantial rate of sampling error and observer variations [6]. In recent years, methods for indirect assessment of liver fibrosis by non-invasive means have been introduced [7]. Scoring systems, based on laboratory tests and patients’ medical history, are simple and non-expensive alternative methods for determining the extent of liver fibrosis. Furthermore, the uneven distribution of fibrosis throughout the liver in NAFLD might result in biopsy related sampling variability, suggesting that non biopsy-based scoring systems may represent a more accurate reflection of global liver fibrosis [8].

The AST-to-Platelet Ratio Index (APRI) and fibrosis 4 calculator (FIB-4) score were originally designed for patients with chronic hepatitis C virus (HCV) infection, but several studies have demonstrated reasonable utility in assessing fibrosis in NAFLD patients, as well [9], [10]. In contrast to the NAFLD-dedicated NAFLD fibrosis score (NFS), APRI score is not based on clinical or epidemiological parameters but is rather relied on patients’ AST level and platelets count [11]. The frequent mild inflammatory activity in patients with NAFLD [12] may result in lower AST levels as compared to HCV patients, and therefore disproportionally low numeric APRI score for a given fibrosis stage. On the other hand, a recent study found portal hypertension in 12% of patients with NAFLD who had no or only mild fibrosis on liver biopsy [13]. This suggests that a fraction of NAFLD patients might develop thrombocytopenia without advanced fibrosis, resulting in a disproportionally high APRI score relative to their actual fibrosis stage.

The aim of this study was to evaluate the performance of APRI and FIB-4 scores in predicting the liver fibrosis stage in NAFLD patients and to compare the sensitivity and specificity of those scores in NAFLD patients to those in patients with chronic HCV infection.

Section snippets

Study design

This retrospective study was approved by the local institutional review board (IRB) according to the local regulations. All documented liver biopsy results performed from August 2005 to December 2012 and patients’ demographic, clinical and laboratory data, obtained from their electronic records, were reviewed. After an extensive review of the patients’ medical records, only those with unequivocal diagnosis of NAFLD or chronic HCV infection were included in the analysis.

In NAFLD patients, other

Patients’ characteristics according to their liver fibrosis stage

1479 liver biopsies, performed at our institute from August 2005 to December 2012, were reviewed. 153 patients with biopsy-proven NAFLD and 297 patients with biopsy-proven HCV infection were included in the current analysis (Fig. 1). Table 1 outlines the baseline characteristics of the study population. Advanced fibrosis was found in 32 (20.9%) and 52 (17.5%) of the NAFLD and HCV patients, respectively, as determined by liver histology.

As expected, in both groups patients with advanced fibrosis

Discussion

In this study, based on a large cohort of HCV and NAFLD patients with all stages of hepatic fibrosis, we found that APRI score is a good predictor for advanced fibrosis among NAFLD patients, although its performance is modestly inferior as compared to patients with chronic HCV infection. In addition, our data suggest that APRI score is not a good discriminator between intermediate fibrosis stages in patients with NAFLD as compared to its performance in patients with chronic HCV infection. A low

Conflicts of interest

None declared.

References (19)

There are more references available in the full text version of this article.

Cited by (42)

  • Acute upper gastrointestinal bleeding due to portal hypertension in children: What is the best timing of endoscopy?

    2022, Digestive and Liver Disease
    Citation Excerpt :

    In our study, we used noninvasive markers of fibrosis/cirrhosis to evaluate the severity of liver disease and we observed that around 50% of episodes had high index of APRI and around 75% had high index of AAR, demonstrating the severity hepatic damage of patients in the studied episodes. APRI and AAR have been reported to assess the degree of liver fibrosis/cirrhosis and to predict for variceal bleeding in adult and pediatric population [16,27–31]. In contrast, Moura et al., in a period of 15 years, identified 70 episodes of bleeding from esophageal varices in 57 patients with portal hypertension, with a higher percentage of first episodes of AUGIB (67%) than that of the present study.

  • First-trimester aspartate aminotransferase to platelet ratio index in predicting intrahepatic cholestasis in pregnancy and its relationship with bile acids: A pilot study

    2021, European Journal of Obstetrics and Gynecology and Reproductive Biology
    Citation Excerpt :

    The APRI score is able to predict the development of fibrosis in the liver, but unable to predict the development of fibrosis in non-alcoholic fatty liver disease. Use of the APRI score for the prediction of ICP has been investigated despite the lack of fibrosis [14–16]. In this study, as ICP is a liver-specific disease, the authors attempted to diagnose ICP using the APRI score obtained from blood tests in the first trimester.

View all citing articles on Scopus
View full text